Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.
Hans-Peter
HP
Hartung
Orhan
O
Aktas
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D006801:Humans; D015337:Multicenter Studies as Topic / Q000379:methods / Q000639:trends; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000639:trends; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab